UPDATE: Morgan Keegan Lowers PT on Haemonetics to $65

Morgan Keegan is out with its report today on Haemonetics HAE, lowering its PT from $76 to $65. In its report, Morgan Keegan writes, "Although the decline in the stock appears overdone, with double-digit EPS growth not likely until the fiscal 4Q, we maintain our Market Perform rating. Our price target is revised to $65 from $76." Shares of HAE closed Monday at $58.36.